Orphan drugs: Unmet societal need for non-profitable privately supplied new products-Reference-Cited by-同舟云学术

Orphan drugs: Unmet societal need for non-profitable privately supplied new products

Published:2007-04 Issue:3 Volume:36 Page:336-354
ISSN:0048-7333
Container-title:Research Policy
language:en
Short-container-title:Research Policy

Author:

Moors Ellen H.M.,Faber Jan

Publisher

Elsevier BV

Subject

Management of Technology and Innovation,Management Science and Operations Research,Strategy and Management

Reference42 articles.

1. Alcimed, 2004. Study on Orphan Drugs. Phase I. Overview of the Conditions for Marketing Orphan Drugs in Europe, http://ec.europa.eu/enterprise/pharmaceuticals/index_en.htm.

2. Social Choice and Individual Values;Arrow,1963

3. New European rules on orphan drugs;Binns;Pharmaceutical Science & Technology Today,2000

4. BioPartner, 2005. The Netherlands life sciences report 2005. New challenges ahead. BioPartner Network.

5. Equity, access and economic evaluation in rare diseases. The impact of orphan drug legislation on health policy and patient care;Bosanquet;Pharmaceutical Development and Regulation,2003

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Using Artificial Intelligence to Advance the Research and Development of Orphan Drugs;Businesses;2024-09-09

2. The Amplified Effect of Market Size on Innovation Along the Supply Chain: The Case of Pea and Wheat Seed Innovation in France;2023

3. Social pharmaceutical innovation and alternative forms of research, development and deployment for drugs for rare diseases;Orphanet Journal of Rare Diseases;2022-09-05

4. Methodology for constructing scenarios for health policy research: The case of coverage decision-making for drugs for rare diseases in Canada;Technological Forecasting and Social Change;2021-10

5. A systematic review of moral reasons on orphan drug reimbursement;Orphanet Journal of Rare Diseases;2021-06-30